EN / JP

Top＞ニュース 一覧
ニュース 一覧
2025.10.19
2025 European Society for Medical Oncology (ESMO) Annual Congress: Presentation of Subgroup Analysis Results from the Phase 2 Clinical Trial of <i>Nanvuranlat</i> Suggesting Patient Selection Criteria for the Global Phase 3 Clinical Trial
2025.08.25
Notice of Resignation of Representative Director Keiichi Masuya and New Management Structure
2025.07.07
J-Pharma Raises an Additional 470 Million Yen Through Third-Party Allotment and Exercise of Stock Option Rights – Total Funding Reaches Approximately 13.4 Billion Yen
2025.06.30
Notice of Board of Directors Appointments
2025.06.10
BREAKFAST MEETING for Prospective Investigators during ASCO~First Step to Start U.S. Phase 3 Clinical Trial of LAT1 Inhibitor NANVURANLAT for Advanced Biliary Tract Cancer~
2025.06.02
Office Relocation Notification
2025.05.23
Positive Response Received from U.S. FDA at CMC Type-C Meeting for Novel Anticancer Candidate Drug Nanvuranlat – Important progress toward the start of Phase III Clinical Trial in the U.S.
2025.04.01
J-Pharma appoints Keiichi Masuya as Representative Director and Co-CEO, and transits to a new management structure
2025.04.01
J-Pharma Raises Maximum ¥5.77 Billion in Funding Accelerates Global Development of LAT1 Inhibitors
2025.02.26
Notice of Board of Directors Appointments
1 2 3 4 5 6 7